Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Squamous Non-small Cell Lung Cancer × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 31 Carcinoma, Non-Small-Cell Lung 20 Melanoma 16 Squamous Cell Carcinoma of Head and Neck 15 Colorectal Neoplasms 15 Urinary Bladder Neoplasms 10 Prostatic Neoplasms 9 Breast Neoplasms 9 Small Cell Lung Carcinoma 8 Lung Neoplasms 8 Liver Neoplasms 8 Carcinoma, Renal Cell 8 Neoplasms 7 Diabetes Mellitus, Insulin-Dependent, 12 7 Biliary Tract Neoplasms 7 Pancreatic Neoplasms 6 Head and Neck Neoplasms 6 Cholangiocarcinoma 6 Ovarian Neoplasms 5 Uterine Cervical Neoplasms 4 Neoplasm Metastasis 4 Mesothelioma, Malignant 4 Fallopian Tube Neoplasms 4 Adenocarcinoma Of Esophagus 4 Stomach Neoplasms 3 Mesothelioma 3 Carcinoma, Transitional Cell 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Testicular Neoplasms 2

Interventions

Paclitaxel 2 Carboplatin 2 tremelimumab 1 pembrolizumab 1 necitumumab 1 envafolimab 1 durvalumab 1 Nivolumab 1 Gemcitabine 1 Endostatins 1 Drug Therapy 1 Cisplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03319316 2022-01-10

SOLUTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡